U.S. equities staged a broad rebound on Wednesday, with the S&P 500 climbing 0.60% to 7,737.65 by 12:18 p.m. EDT, recovering approximately 86% of the 53.30-point loss sustained in the previous session. The recovery was notable not just for its scope, but for the sectors driving it—healthcare surged while technology remained flat, marking a departure from the tech-led rally that has characterized much of this year.
The benchmark index closed just 7.41 points below Monday's level, but the composition of the advance was telling. Healthcare shares jumped 2.9% to an all-time high, while the technology sector, which accounts for 36.8% of the index as of July 31, showed no change. Semiconductors declined 1.3%, underscoring the uneven nature of the rebound. Market breadth improved, with advancers outpacing decliners on the NYSE by a 2.42-to-1 ratio, and the S&P 500 recorded 18 new highs without a single new low.
The healthcare surge was led by Moderna (NASDAQ:MRNA), which more than doubled following positive results from a melanoma vaccine trial conducted with Merck (NYSE:MRK). Merck shares advanced 11.2%, propelling the sector to record territory. This rotation into defensive growth names came as technology faced headwinds, with Broadcom (NASDAQ:AVGO) dropping 4% after Marvell Technology (NASDAQ:MRVL) awarded Alphabet's Google (NASDAQ:GOOGL) a warrant tied to a $12.18 billion holding. The Philadelphia Semiconductor Index ended 1.3% lower.
The market's response to interest rates remains a key theme. Elevated long-term yields reduce the present value of future technology earnings, a dynamic that has weighed on the sector. Robert Pavlik of Dakota Wealth noted that when interest rates creep up, those projections lose worth. The 30-year Treasury yield stood at 5.203%, down from Tuesday's 19-year high, but still at levels that keep pressure on growth stocks. The 10-year yield held at 4.655%.
In a move to ease short-term strain, the Treasury increased the scheduled repurchase of specific 10-to-30-year securities, raising the minimum to $4 billion per buyback. The revised approach will be in effect from September 9 to November 4. However, Joseph Purtell of Neuberger Berman cautioned that such buying offers only temporary relief and does not address the underlying low demand for long-term bonds or fiscal shortfalls.
The Federal Reserve's July meeting minutes, released at 2 p.m., reinforced a cautious stance. Some officials supported a rate hike in July, while several others indicated that further tightening would likely be necessary unless inflation moves back toward the 2% target. Markets showed limited immediate reaction to the minutes, which were largely in line with expectations.
Analyst targets for the S&P 500 by year-end range from 7,900 to 8,100, implying potential upside of just 2.1% to 4.7% from midday levels. Citigroup (NYSE:C) sees 8,100, JPMorgan (NYSE:JPM) and Goldman Sachs (NYSE:GS) both target 8,000, and UBS (NYSE:UBS) projects 7,900. These modest gains suggest that earnings growth, rather than multiple expansion, will be the primary driver of returns, especially with the 10-year yield near 4.655%.
Risks remain skewed to the downside. A fresh surge in oil prices could push inflation expectations higher and lift long-term yields, while another round of chip stock declines would weigh heavily on the index given technology's outsized weight. Wednesday's rebound lifted the headline index but failed to revive its previous leadership. Investors now require more widespread earnings momentum, rather than just a single day of lower yields, to sustain the recovery.
